 |
Hot Pursuit
13-Feb-23
|
|
|
|
|
|
|
|
|
|
|
|
Biocon says USFDA issues CRL for biologics license application for Bevacizumab
|
|
The U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) for Bevacizumab filed by partner Viatris (Mylan).
|
|
|
|
|
|
"The U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) for Bevacizumab filed by our partner Viatris (Mylan). The CRL informs the need for a satisfactory resolution of the observations made during the facility inspection conducted in August, 2022. We have submitted a comprehensive Corrective and Preventive Action (CAPA) plan, to the agency and are confident of addressing the observations within the stipulated timeframe. The CRL did not identify any outstanding scientific issues with the dossier," - Biocon Biologics spokesperson said.
Biocon is an innovation-led, global biopharmaceutical company committed to enhancing affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune diseases.
The company had reported a net profit (before exceptional items) of Rs 168 crore in Q2 FY23, down by 10% from Rs 188 crore in Q2 FY22. Revenue from operations increased by 26% YoY to Rs 2,320 crore during the quarter.
The Biocon scrip fell 0.29% to settle trade at Rs 242.45 on Friday, 10 February 2023.
|
|
|
|
Previous News |
Biocon
(
Results
-
Analysis
17-May-24
10:41
)
|
|
|
Biocon Ltd up for third consecutive session
(
Hot Pursuit
-
11-Sep-24
13:06
)
|
|
|
Biocon signs exclusive licensing and supply agreement with Handok
(
Corporate News
-
24-May-24
09:06
)
|
|
|
Biocon Ltd up for five straight sessions
(
Hot Pursuit
-
19-Feb-24
13:00
)
|
|
|
Biocon Ltd soars 1.22%, rises for fifth straight session
(
Hot Pursuit
-
27-Mar-24
13:00
)
|
|
|
Biocon Ltd soars 3.74%, rises for third straight session
(
Hot Pursuit
-
02-Jan-24
13:05
)
|
|
|
Biocon acquires facility of Eywa Pharma in US for $7.7 mln
(
Hot Pursuit
-
02-Sep-23
14:59
)
|
|
|
Biocon to conduct board meeting
(
Corporate News
-
18-Jul-24
10:37
)
|
|
|
Biocon gets US FDA approval for market generic version of anti-cancer drug
(
Hot Pursuit
-
07-Feb-24
09:35
)
|
|
|
Biocon gains as arm takes over Viatris' biosimilar biz in over 70 countries
(
Hot Pursuit
-
06-Jul-23
12:03
)
|
|
|
Biocon inks pact with Juno Pharma for commercialization of Liraglutide
(
Hot Pursuit
-
09-Oct-23
10:11
)
|
|
|
|
|
|
Other Stories |
|
|
|
|
|
|
|
|
|
|
|
|
|